Acino ? Delivering Health

More documents

Recommendations

Info

The manufacturing, R&D and corporate office facilities in Aesch 20
Acquired business perfectly fits Acino In line with Acino’s 3-pillar growth strategy Identical approach with regard to branded drugs/“branded generics” “Swissness” efficiently promoted in emerging markets: – Swiss/EU quality standards a differentiating feature – Preference for drugs manufactured in Switzerland/EU Portfolio for emerging markets: – Acino very active in the registration of products from own development – Product portfolios complement each other ideally Synergies in the commerical infrastructure; highly motivated Mepha / Cephalon sales team Expansion of R&D know-how: products with sophisticated galenical forms, complementary to Acino’s own expertise 21
Page 1 and 2: Acino - Delivering Health Annual Re
Page 3 and 4: 2011 operating performance EUR mill
Page 5 and 6: Balance sheet EUR million 31.12.201
Page 7 and 8: R&D and development pipeline Zurich
Page 9 and 10: In-house technologies Complex, soli
Page 11 and 12: In-house technologies Bio-degradabl
Page 13 and 14: From 2013 onwards 2-3 projects per
Page 15 and 16: “Old” Acino: highly dependent o
Page 17 and 18: 3-pillar business model of Acino Ac
Page 19: The acquisition includes: The marke
Page 23 and 24: The “new” Acino: broad customer
Page 25 and 26: Geographic break-down of revenue Ma
Page 27 and 28: Our past and future strengths Expan
Page 29 and 30: Key Facts: Acino TODAY Fourth large
Page 31: Acino - Delivering Health Thank you

Acino ? Delivering Health

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?